KARACA, H. 2011. Phase II study of lapatinib in combination with ErbB2-amplified recurrent or metastatic breast cancer (Turkish Oncology Group Trial) (Abstract No: e13079) J Clin Oncol 29 (suppl). Annual Meeting of American Society of Clinical Oncology , (United States Of America), 1.

KARACA, H., (2011). Phase II study of lapatinib in combination with ErbB2-amplified recurrent or metastatic breast cancer (Turkish Oncology Group Trial) (Abstract No: e13079) J Clin Oncol 29 (suppl) . Annual Meeting of American Society of Clinical Oncology (pp.1). , United States Of America

KARACA, Halit. "Phase II study of lapatinib in combination with ErbB2-amplified recurrent or metastatic breast cancer (Turkish Oncology Group Trial) (Abstract No: e13079) J Clin Oncol 29 (suppl)," Annual Meeting of American Society of Clinical Oncology, United States Of America, 2011

KARACA, Halit. "Phase II study of lapatinib in combination with ErbB2-amplified recurrent or metastatic breast cancer (Turkish Oncology Group Trial) (Abstract No: e13079) J Clin Oncol 29 (suppl)." Annual Meeting of American Society of Clinical Oncology , United States Of America, pp.1, 2011

KARACA, H. (2011) . "Phase II study of lapatinib in combination with ErbB2-amplified recurrent or metastatic breast cancer (Turkish Oncology Group Trial) (Abstract No: e13079) J Clin Oncol 29 (suppl)." Annual Meeting of American Society of Clinical Oncology , United States Of America, p.1.

@conferencepaper{conferencepaper, author={Halit KARACA}, title={Phase II study of lapatinib in combination with ErbB2-amplified recurrent or metastatic breast cancer (Turkish Oncology Group Trial) (Abstract No: e13079) J Clin Oncol 29 (suppl)}, congress name={Annual Meeting of American Society of Clinical Oncology}, city={}, country={United States Of America}, year={2011}, pages={1} }